MAIA Biotechnology (MAIA) vs Nomad Power Solutions (NMAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 11.2% versus a loss of 36.5%. MAIA Biotechnology is the larger company by market cap ($75.3 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | NMAD |
|---|---|---|
| Share price | $1.22 | $4.53 |
| Market cap | $75.33M | $72.94M |
| 1-day change | +6.09% | +6.09% |
| YTD return | -24.84% | +8.65% |
| 1-year return | -36.46% | -11.23% |
| 5-year return | — | -77.17% |
| Forward P/E | 1.10 | — |
| EPS (TTM) | $-0.62 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $8.38 |
| 52-week low | $0.87 | $2.36 |
| Distance from 52-week high | -61.76% | -45.94% |
| Analyst consensus | none | — |
| Avg. price target upside | +883.61% | — |
| Average volume | 527.89K | 273.42K |
| Shares outstanding | 61.74M | 16.10M |
| Employees | 13 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed MAIA by 25.2 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
MAIA vs NMAD FAQ
Which is bigger, MAIA Biotechnology or Nomad Power Solutions?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $75.33M compared with $72.94M for Nomad Power Solutions (NMAD).
Which stock has performed better over the past year, MAIA or NMAD?
NMAD returned -11.23% over the past 12 months, compared with -36.46% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and Nomad Power Solutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.